News

“Time Saved” Calculations to Improve Decision-Making in Progressive Disease Studies

Disease modifying therapies (DMTs) are a focus of research for Alzheimer’s disease (AD). DMTs are expected to change the trajectory of disease progression and slow rates of clinical decline (1-3). DMTs may be most beneficial when treatment is begun early in disease to maintain higher levels of function longer and for patients to derive the most total benefit from treatment.